Association between serum hepcidin-25 and primary resistance to erythropoiesis-stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial.
Gummer J, Trengove R, Pascoe EM, Badve SV, Cass A, Clarke P, McDonald SP, Morrish AT, Pedagogos E, Perkovic V, Reidlinger D, Scaria A, Walker R, Vergara LA, Hawley CM, Johnson DW, Olynyk JK, Ferrari P; HERO Study Collaborative Group.
Gummer J, et al. Among authors: johnson dw.
Nephrology (Carlton). 2017 Jul;22(7):548-554. doi: 10.1111/nep.12815.
Nephrology (Carlton). 2017.
PMID: 27171136
Clinical Trial.